BMO Capital initiated coverage of IGM Biosciences (IGMS) with an Outperform rating and $21 price target IGM is a clinical-stage biotechnology ...

Fintel reports that on December 6, 2024, BMO Capital initiated coverage of IGM Biosciences (NasdaqGS:IGMS) with a Outperform ...

Quest Partners LLC lessened its stake in IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 86.2% in the 3rd quarter, ...

Fintel reports that on December 6, 2024, BMO Capital initiated coverage of IGM Biosciences (NasdaqGS:IGMS) with a Outperform recommendation. As of December 3, 2024, the average one-year price ...

IGM Biosciences has pivoted from cancer therapeutics to autoimmune diseases despite setbacks, showing a 25% stock increase since last October. Click for more on IGMS.

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies MOUNTAIN VIEW, Calif., Nov. 04 ...

IGM Biosciences, Inc.'s (NASDAQ:IGMS) Chief Financial Officer, Tahir Misbah, recently sold shares of the company stock, according to the latest SEC filings. The ...